Purpose: To evaluate the clinical effect of DT Light-Post system in prosthodontic treatment for the residual root and crown.
Methods: 193 patients with 287 anterior teeth and premolars were involved, including 195 residual crowns and 92 residual roots. After complete root canal therapy, the teeth were treated with DT Light-Post system and all-ceramic crowns. Results of residual crowns and residual roots were analyzed statistically with SAS 6.12 software package for Chi-square test.
Results: After observation for 1 to 3 years, 6 crowns with core and post were lost in 195 residual crowns, and 17 lost in 92 residual roots. And all the lost cases were cemented with chemo-setting adhesives, and none of them lost again in one year. On the other hand, no post or root broken were found. The total successful rate was 91.98%. And the lost rate of crowns in patients with residual crowns was significantly lower than those with residual root (P=0.001).
Conclusion: Fiber post is an idea method for post-and-core restorations, the successful rate is affected significantly by the indication, the type of adhesion and the adhesive technique.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Thermal stresses in porcelain veneered lithium disilicate and zirconia dental crowns: Comparative analysis using a validated viscoelastic finite element model.
J Mech Behav Biomed Mater
January 2025
Department of Civil and Environmental Engineering, University of Connecticut, Storrs, CT, 06269, USA. Electronic address:
This study aims to investigate the effects of material compatibility, variable cooling rates, and crown geometry on thermal stress development in porcelain-veneered lithium disilicate (PVLD) and porcelain-veneered zirconia (PVZ) dental crown systems, and subsequently anticipate parameters for their optimum performance. An anatomically correct 3D crown model was developed from STL files generated using 3D scans of the experimental crown sample. Next, the viscoelastic finite element model (VFEM) based on the 3D crown model was developed and validated for anatomically correct bilayer PVLD and PVZ crown systems.
View Article and Find Full Text PDFSurvival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
N Engl J Med
January 2025
From the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation (C.E.G., E.P.M., N.W., P.R., I.L.W., A.M.B.) and University of Pittsburgh School of Medicine-UPMC Hillman Cancer Center (C.E.G., N.W., P.R., A.M.B.) - both in Pittsburgh; AGO-B and Helios Klinikum Berlin-Buch, Berlin (M.U.), the National Center for Tumor Diseases, Heidelberg University Hospital, and German Cancer Research Center, Heidelberg (A.S.), Evangelische Kliniken Gelsenkirchen, Gelsenkirchen (H.H.F.), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast and Sana Klinikum Offenbach, Offenbach (C.J.), the Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), German Breast Group, Neu-Isenburg (P.W., S.L.), and the Center for Hematology and Oncology Bethanien, Goethe University, Frankfurt (S.L.) - all in Germany; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (C.-S.H.); Instituto do Câncer do Estado de São Paulo, São Paulo (M.S.M.); Orlando Health Cancer Institute, Orlando, FL (E.P.M.); Hospital Universitario La Paz-Instituto de Investigación del Hospital Universitario La Paz, Madrid (A.R.); L'Institut du Cancer de Montpellier-Val d'Aurelle, Montpellier (V.D.), Institut Bergonié, INSERM Unité 1312, and Université de Bordeaux UFR Sciences Médicales, Bordeaux (H.R.B.) - all in France; Providence Cancer Institute, Portland, OR (A.K.C.); the Department of Surgery, Oncology, and Gastroenterology, University of Padua, and Oncology 2, Istituto Oncologico Veneto IRCCS, Padua (V.G.), and the Cancer Center Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo (E.R.C.) - all in Italy; Stanford University School of Medicine, Stanford, CA (I.L.W.); the National Cancer Institute, Mexico City (C.A.-S.); Yale University School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, New Haven, CT (M.P.D.); the All-Ireland Cooperative Oncology Research Group (J.P.C.), and the Oncology Unit, Cancer Clinical Trials and Research Unit, Beaumont RCSI Cancer Centre, and Cancer Trials Ireland (B.T.H.) - all in Dublin; Fudan University Shanghai Cancer Center, Shanghai, China (Z.S.); Institute for Oncology and Radiology of Serbia, Belgrade (L.S.); Grupo Médico Ángeles, Guatemala City, Guatemala (H.C.-S.); Roche Products, Welwyn Garden City, United Kingdom (A.K., A.S.); and F. Hoffmann-La Roche, Basel, Switzerland (C.L., T.B., B.N., E.R.).
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with trastuzumab alone.
Methods: We randomly assigned patients with HER2-positive early breast cancer with residual invasive disease in the breast or axilla after neoadjuvant systemic treatment with taxane-based chemotherapy and trastuzumab to receive T-DM1 or trastuzumab for 14 cycles.
Excess cement and peri-implant disease: A cross-sectional clinical endoscopic study.
J Periodontol
January 2025
Department of Biomedical and Neuromotor Sciences, School of Dentistry - Division of Periodontology and Implantology, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Background: Crown cementation is a common technique for implant-supported prosthodontics. However, for possible slipping of the cement below the mucosal margin, its thorough removal poses some issues. The objective of this study was to evaluate the presence of submucosal cement residues in patients with peri-implant disease by endoscopic visualization and to investigate the potential correlation between the pathological scenario and the spatial position of cement residues.
View Article and Find Full Text PDFRedosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial.
Int J Mol Sci
January 2025
Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping University, 581 83 Linköping, Sweden.
Immunotherapies aimed at preserving residual beta cell function in type 1 diabetes have been successful, although the effect has been limited, or raised safety concerns. Transient effects often observed may necessitate redosing to prolong the effect, although this is not always feasible or safe. Treatment with intralymphatic GAD-alum has been shown to be tolerable and safe in persons with type 1 diabetes and has shown significant efficacy to preserve C-peptide with associated clinical benefit in individuals with the human leukocyte antigen DR3DQ2 haplotype.
View Article and Find Full Text PDFEffect of cementation technique and cement type on the amount of excess cement in implant-supported cement-retained crown restorations: An in vitro study.
J Prosthet Dent
December 2024
Professor, Department of Prosthodontics, Faculty of Dentistry, Gazi University, Ankara, Turkey.
Statement Of Problem: Excess cement in implant-supported restorations can lead to peri-implant diseases, and its removal remains a clinical challenge. The optimum method of minimizing excess cement is unclear.
Purpose: The purpose of this in vitro study was to compare 3 cementation techniques and 3 cement types and measure excess cement.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!